Expert Details ‘Pervasive’ Racial/Ethnic Opioid Access Disparities in Cancer
February 07, 2023

An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.

Atezolizumab Plus Bevacizumab Shows Potential in TMB-H Nonsquamous NSCLC
February 07, 2023

Findings from the phase 2 TELMA trial suggest that atezolizumab plus bevacizumab yields robust, long-lasting outcomes for patients with metastatic nonsquamous tumor mutational burden–high non–small cell lung cancer.

Multidimensional Rehabilitation Appears Feasible/Safe in Blood Cancers
February 07, 2023

Findings from a randomized trial indicate that therapeutic education plus physical activity are safe, feasible, and potentially effective for patients with hematologic cancer.

FDA Accepts BLA for Denosumab Biosimilar for Prevention of Bone Loss in Cancer
February 07, 2023

A biologic license application for a biosimilar of denosumab is under review by the FDA for managing osteoporosis and treatment-induced bone loss in those with cancer.

Expert Highlights Need for Bias Training to Reduce Opioid Access Disparities in Cancer
February 07, 2023

An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.

Induction Therapy in Transplant-Ineligible NDMM
February 06, 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM
February 06, 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Favorable Outcomes Associated With Early MRD Following Allo-SCT in AML
February 06, 2023

Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant.

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma
February 06, 2023

The FDA gives orphan drug designation to BEA-17, an investigational small molecule degrader that may benefit those with a common and aggressive brain tumor.

Investigators Resubmit BLA for Remestemcel-L in Pediatric Acute GVHD
February 06, 2023

A biologic license application that has been resubmitted to the FDA for remestemcel-L in pediatric graft-versus-host disease includes new long-term survival data from a phase 3 clinical trial.